Dorien Geusens , Daan Dierickx , Saskia Carton , Eric Van Cutsem , Jeroen Dekervel
{"title":"Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review","authors":"Dorien Geusens , Daan Dierickx , Saskia Carton , Eric Van Cutsem , Jeroen Dekervel","doi":"10.1016/j.clcc.2024.01.005","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>As there are increasingly more indications for immune checkpoint inhibitors (ICI), immune related adverse events will also become more prevalent. ICI induced haemophagocytic lymphohistiocytosis (HLH) has been described in case reports and pharmacovigilance database reviews. Literature regarding rechallenge of ICI after resolution of HLH is limited to a few cases.</p></span></li><li><span>•</span><span><p>With this case report, we want to highlight the need for early diagnosis and treatment. We also showed that ICI may be rechallenged safely, provided close monitoring and discussion with the patient.</p></span></li><li><span>•</span><span><p>This article might impact on clinical practice by increasing awareness about ICI induced HLH and contributing to the body of literature regarding this topic.</p></span></li></ul></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002824000057","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
•
As there are increasingly more indications for immune checkpoint inhibitors (ICI), immune related adverse events will also become more prevalent. ICI induced haemophagocytic lymphohistiocytosis (HLH) has been described in case reports and pharmacovigilance database reviews. Literature regarding rechallenge of ICI after resolution of HLH is limited to a few cases.
•
With this case report, we want to highlight the need for early diagnosis and treatment. We also showed that ICI may be rechallenged safely, provided close monitoring and discussion with the patient.
•
This article might impact on clinical practice by increasing awareness about ICI induced HLH and contributing to the body of literature regarding this topic.